Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution
Amgen has successfully concluded its monumental $27.8 billion acquisition of Horizon Therapeutics, triumphing over a legal challenge posed by the ...
Lotte Biologics to Construct 3 New Plants by 2030 After Land Purchase, Boosting Korean CDMO Capacity
Korean Contract Development and Manufacturing Organization (CDMO), Lotte Biologics, is embarking on an ambitious growth trajectory, aiming to achieve a ...
BMS and Paradigm partner to bring clinical trials to community health providers
Bristol Myers Squibb (BMS) has embarked on a transformative collaboration with Paradigm, a groundbreaking startup focused on reimagining the clinical ...
Precede Biosciences raises $57M to advance liquid biopsy platform
A promising new venture, emerging from the esteemed Dana-Farber Cancer Institute, is set to revolutionize the landscape of cancer diagnostics ...
Amgen’s Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
Medable and Pluto Health partner to improve clinical trial recruitment
Medable, a trial software company, is teaming up with Pluto Health, a health data provider, to streamline and expedite patient ...
Impel Pharmaceuticals explores sale options amid financial challenges
Despite its efforts to resolve its financial challenges, Impel Pharmaceuticals remains at risk of bankruptcy and is launching a last-ditch ...
Innate Pharma halts lymphomas trials after patient death, but key study continues
Innate Pharma has encountered a safety issue in its lymphoma program, resulting in the FDA imposing a partial clinical hold ...
Neurocrine reports positive phase 3 data for hyperplasia drug in children
Just a month after the successful outcome of Neurocrine Biosciences’ phase 3 study for crinecerfont in adults with hyperplasia, the ...
Kyowa Kirin to buy Orchard Therapeutics for $387M, expanding gene therapy portfolio
Kyowa Kirin has responded to the need to strengthen its late-phase pipeline by finalizing a deal to acquire Orchard Therapeutics ...
AbbVie acquires mitochondria biotech to boost Parkinson’s research
AbbVie has made a significant move in the field of Parkinson’s disease by acquiring Mitokinin for an upfront payment of ...
uniQure cuts staff and R&D projects to extend gene therapy cash runway
uniQure, a biotech company focused on gene therapy, is implementing a significant workforce reduction as part of a strategic restructuring ...
EQRx’s ambitious plan to sell cheap drugs falls apart after $4.2B deal
EQRx, a biotech company founded with the ambitious mission of developing affordable medicines, recently found itself embroiled in a complex ...
Apellis’ GA Drug Syfovre Displays Signs of Recovery Amid Challenges
Apellis Pharmaceuticals, which recently faced workforce reductions due to concerns surrounding its groundbreaking geographic atrophy (GA) drug, Syfovre, is reporting ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
Colombia seeks to slash HIV drug costs by overriding ViiV’s patent
Colombia has taken a significant step in response to a pricing dispute with GSK’s ViiV Healthcare regarding the HIV medication ...
Viatris challenges Novo Nordisk’s patent on diabetes drug semaglutide
In Viatris’ ambitious bid to be the first to introduce generic versions of Novo Nordisk’s blockbuster diabetes and obesity drugs, ...
Lonza to boost ADC production capacity and hire 180 new staff
Despite the unexpected departure of Lonza’s CEO last month, the Swiss Contract Development and Manufacturing Organization (CDMO) remains a force ...
Lagevrio, the first oral COVID-19 drug, to be available in US soon
As anticipated, the US government is in the process of phasing out its distribution of COVID-19 treatments. Merck & Co.’s ...
Boehringer Ingelheim Adopts Dual-Pricing Strategy with Launch of Unbranded Humira Biosimilar
Boehringer Ingelheim, the company that recently introduced the first interchangeable biosimilar to AbbVie’s blockbuster drug Humira, is now embracing a ...
Sandoz’s Subdued Market Entrance After Splitting from Novartis
Sandoz has successfully completed its separation from Novartis after extensive preparations lasting over a year. However, the initial valuation on ...
Eli Lilly Reshuffles C-Suite Leadership Amid Crucial Mounjaro Decision Looming
Eli Lilly is undergoing leadership changes in its diabetes and obesity division as it anticipates a significant FDA decision in ...
Exscientia Shifts Focus: Consolidates ‘Rapidly Emerging Pipeline’ to Emphasize 2 Key Oncology Programs
Exscientia, an AI-driven precision medicine company, is streamlining its pipeline to concentrate on the highest-value opportunities. The company is focusing ...
NIH-Backed Study Reveals Digital Screening App Accurately Identifies Autism 88% of the Time
A tablet-based application called SenseToKnow has the potential to address disparities in autism spectrum disorder (ASD) diagnoses across different genders, ...
Novartis Explores Possible Sale of Diagnostic Radiopharmaceutical Agents, Reports Bloomberg
Novartis is reportedly exploring the sale of a portion of its diagnostic radiopharmaceutical agents held under the Advanced Accelerator Applications ...
Kezar Faces Significant Staff Loss, CEO Persists in Advancing Lead Lupus Candidate to Phase 2 Milestone
Kezar Life Sciences is embarking on a significant restructuring plan aimed at preserving cash resources over the next two years ...
Lilly Makes a Splash in Radiopharmaceuticals with $1.4B Acquisition of Point Biopharma
Eli Lilly is making a significant foray into the radiopharmaceutical cancer therapeutic sector with its acquisition of Point Biopharma Global ...
FDA Approves 5-Minute Tests for Monitoring Humira and Remicade Doses in Inflammatory Bowel Disease Patients
The FDA has recently granted two de novo clearances to ProciseDx, marking a significant advancement in personalized medicine for patients ...
Sanofi Joins Forces with Teva, Merck, and Roivant in $500M Deal for Bowel Disease Race
Sanofi is making significant financial moves in the pharmaceutical landscape. Just one day after sealing a $175 million vaccine deal, ...
